Antares' (ATRS) Vibex QuickShot auto injector restored and maintained testosterone levels in a Phase II study of 29 patients. The testosterone-replacement market was worth $2.8B in sales in 2013.

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...

Pfizer has tapped Antares Pharma for the development of a self-administered combination drug-device rescue pen for an undisclosed medicine, shortly after investing $465 million in a new sterile ...

Xyosted carries a Boxed Warning regarding blood pressure increases that may potentially increase the risk for major adverse cardiovascular events. The Food and Drug Administration (FDA) has approved ...

Independent analysis examines Fridays' published TRT program structure, delivery format options, and what clinical research indicates for men evaluating prescription testosterone pathways heading into ...

* Antares Pharma Inc - submitted a new drug application (nda) to U.S. Food And Drug Administration (FDA) for quickshot testosterone Sign up here. * Antares Pharma Inc - quickshot testosterone auto ...